Cefuroxime 500 mg Tablets

Product Description

Cefuroxime axetil is indicated for the treatment of the infections listed below in adults and children from the
age of 3 months (see sections 4.4 and 5.1).
- Acute streptococcal tonsillitis and pharyngitis.
- Acute bacterial sinusitis.
- Acute otitis media.
- Acute exacerbations of chronic bronchitis.
- Cystitis
- Pyelonephritis.
- Uncomplicated skin and soft tissue infections.
- Treatment of early Lyme disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The usual course of therapy is seven days (may range from five to ten days).


Table 1. Adults and children (≥40 kg)


Acute tonsillitis and pharyngitis, acute bacterial sinusitis

250 mg twice daily

Acute otitis media

500 mg twice daily

Acute exacerbations of chronic bronchitis

500 mg twice daily


250 mg twice daily


250 mg twice daily

Uncomplicated skin and soft tissue infections

250 mg twice daily

Lyme disease

500 mg twice daily for 14 days (range of 10 to 21 days)

Table 2. Children (<40 kg)




Acute tonsillitis and pharyngitis, acute bacterial sinusitis

10 mg/kg twice daily to a maximum of 125 mg twice daily

Children aged two years or older with otitis media or, where appropriate, with more severe infections

15 mg/kg twice daily to a maximum of 250 mg twice daily


15 mg/kg twice daily to a maximum of 250 mg twice daily


15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days

Uncomplicated skin and soft tissue infections

15 mg/kg twice daily to a maximum of 250 mg twice daily

Lyme disease

15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)

There is no experience of using Cefuroxime axetil in children under the age of 3 months.


Renal impairment


The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.


Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.

Table 3. Recommended doses for Cefuroxime axetil in renal impairment


Creatinine clearance

T1/2 (hrs)

Recommended dosage

≥30 mL/min/1.73 m2


no dose adjustment necessary (standard dose of 125 mg to 500 mg given twice daily)

10-29 mL/min/1.73 m2


standard individual dose given every 24 hours

<10 mL/min/1.73 m2


standard individual dose given every 48 hours

Patients on haemodialysis


a further standard individual dose should be given



at the end of each dialysis

Hepatic impairment


There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

Method of administration


Oral use


Cefuroxime axetil tablets should be taken after food for optimum absorption.

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
Jarisch-Herxheimer reaction

The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually
self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8). Overgrowth of non-susceptible microorganisms
As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment (see section 4.8).
Antibacterial agent–associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment

for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).
Interference with diagnostic tests

The development of a positive Coomb's Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).
As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.
Important information about excipients

Special care should be taken with phenylketonuric patients because of the aspartame containing coating. Cefuroxime axetil 125 mg coated tablets contain 0.2 mg aspartame per tablet.
Cefuroxime axetil 250 mg coated tablets contain 0.3 mg aspartame per tablet.

Contact Info



Address: 298 West Zhongshan Road.,Ningbo,Zhejiang

Contact Person: Medic Ren



Full name Contact Phone Content